Shao-Lee Lin - 12 Oct 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CUE
Reported as of: 12 Oct 2026
Net transaction value: -$305,490
SEC form: 4
Accepted by SEC: 14 Oct 2026, 21:37:35 UTC
Prior SEC filing: 14 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Shao-Lee Lin

Key filing fact

Shao-Lee Lin filed Form 4 for Cue Biopharma, Inc. (CUE) on 14 Oct 2026.

Key facts

This page summarizes Shao-Lee Lin's Form 4 filing for Cue Biopharma, Inc. (CUE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Oct 2026, 21:37.

Change

Previous filing in this sequence was filed on 14 Aug 2026.
Current net transaction value: -$305,490.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001725092 Primary reporting owner

Lin Shao-Lee

Relationship: Chief Executive Officer, Director
Address: C/O CUE BIOPHARMA, INC., 100 CHESTNUT STREET, SUITE 300, SOMERVILLE
Signature: /s/ Shao-Lee Lin
Signature date: 14 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CUE transaction

Common Stock

Sale

Transaction value: $275,000
Shares: -10,000
Change %: -1.4%
Price: $27.50
Shares after: 695,995
Date: 12 Oct 2026
Ownership: Direct
Footnotes: F1

CUE transaction

Common Stock

Sale

Transaction value: $30,490
Shares: -1,087
Change %: -0.16%
Price: $28.05
Shares after: 694,908
Date: 12 Oct 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.